JP2019516981A - 方法、アレイ、およびその使用 - Google Patents

方法、アレイ、およびその使用 Download PDF

Info

Publication number
JP2019516981A
JP2019516981A JP2018559285A JP2018559285A JP2019516981A JP 2019516981 A JP2019516981 A JP 2019516981A JP 2018559285 A JP2018559285 A JP 2018559285A JP 2018559285 A JP2018559285 A JP 2018559285A JP 2019516981 A JP2019516981 A JP 2019516981A
Authority
JP
Japan
Prior art keywords
weeks
pancreatic cancer
biomarkers
moiety
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018559285A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019516981A5 (cg-RX-API-DMAC10.html
Inventor
カール・ボーレベック
アンナ・サンドストレーム・イェルトソン
クリステル・ヴィングレーン
Original Assignee
イミュノヴィア・アーベー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イミュノヴィア・アーベー filed Critical イミュノヴィア・アーベー
Publication of JP2019516981A publication Critical patent/JP2019516981A/ja
Publication of JP2019516981A5 publication Critical patent/JP2019516981A5/ja
Priority to JP2021106544A priority Critical patent/JP2021165745A/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/5436—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand physically entrapped within the solid phase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Gastroenterology & Hepatology (AREA)
JP2018559285A 2016-05-10 2017-05-10 方法、アレイ、およびその使用 Pending JP2019516981A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021106544A JP2021165745A (ja) 2016-05-10 2021-06-28 方法、アレイ、およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1608192.9 2016-05-10
GBGB1608192.9A GB201608192D0 (en) 2016-05-10 2016-05-10 Method, array and use thereof
PCT/EP2017/061202 WO2017194613A2 (en) 2016-05-10 2017-05-10 Method, array and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021106544A Division JP2021165745A (ja) 2016-05-10 2021-06-28 方法、アレイ、およびその使用

Publications (2)

Publication Number Publication Date
JP2019516981A true JP2019516981A (ja) 2019-06-20
JP2019516981A5 JP2019516981A5 (cg-RX-API-DMAC10.html) 2020-06-25

Family

ID=56297465

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018559285A Pending JP2019516981A (ja) 2016-05-10 2017-05-10 方法、アレイ、およびその使用
JP2021106544A Pending JP2021165745A (ja) 2016-05-10 2021-06-28 方法、アレイ、およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021106544A Pending JP2021165745A (ja) 2016-05-10 2021-06-28 方法、アレイ、およびその使用

Country Status (13)

Country Link
US (2) US20200011872A1 (cg-RX-API-DMAC10.html)
EP (2) EP3907509A3 (cg-RX-API-DMAC10.html)
JP (2) JP2019516981A (cg-RX-API-DMAC10.html)
KR (1) KR20190005858A (cg-RX-API-DMAC10.html)
CN (1) CN109564221A (cg-RX-API-DMAC10.html)
AU (1) AU2017261762A1 (cg-RX-API-DMAC10.html)
BR (1) BR112018073178A2 (cg-RX-API-DMAC10.html)
CA (1) CA3022022A1 (cg-RX-API-DMAC10.html)
GB (1) GB201608192D0 (cg-RX-API-DMAC10.html)
IL (1) IL262824A (cg-RX-API-DMAC10.html)
MX (1) MX2018013621A (cg-RX-API-DMAC10.html)
RU (1) RU2018138639A (cg-RX-API-DMAC10.html)
WO (1) WO2017194613A2 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025534317A (ja) * 2022-09-28 2025-10-15 ヒューベット バイオ，インコーポレーテッド 膵臓癌診断用組成物

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008231575A1 (en) 2007-03-27 2008-10-02 Immunovia Ab Protein signature/markers for the detection of adenocarcinoma
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
CA3127569A1 (en) * 2019-02-18 2020-08-27 The University Of Liverpool Method of diagnosis
AU2020279240A1 (en) 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof
WO2022109105A1 (en) * 2020-11-18 2022-05-27 Pandion Operations, Inc. Madcam targeted therapeutics and uses thereof
JP2024505333A (ja) 2020-12-21 2024-02-06 フリーノム ホールディングス，インク． 結腸細胞増殖障害の早期検出のためのマーカー
WO2022204332A1 (en) * 2021-03-24 2022-09-29 Combangio, Inc. Compositions comprising c-met agonist antibodies and methods for use in ocular treatment
CN117305244B (zh) * 2023-03-28 2025-02-28 湖南省肿瘤医院 人胰腺癌细胞株及其应用
CN120177800B (zh) * 2025-05-23 2025-10-10 四川大学 血液生物标志物cfp在制备急性胰腺炎诊断试剂的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004147656A (ja) * 2002-10-31 2004-05-27 F Hoffmann La Roche Ag 膵癌の診断および治療のための方法、ならびにそれらに有用な組成物
WO2013052480A1 (en) * 2011-10-03 2013-04-11 The Board Of Regents Of The University Of Texas System Marker-based prognostic risk score in colon cancer
WO2014160499A2 (en) * 2013-03-13 2014-10-02 Creatics Llc Methods and compositions for detecting pancreatic cancer
WO2015067969A2 (en) * 2013-11-11 2015-05-14 Immunovia Ab Method, array and use thereof
WO2015171736A2 (en) * 2014-05-07 2015-11-12 University Of Utah Research Foundation Biomarkers and methods for diagnosis of early stage pancreatic ductal adenocarcinoma

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0039578B1 (en) 1980-05-02 1985-04-10 Edward P. Davis Leg aid device
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US5856090A (en) 1994-09-09 1999-01-05 The Scripps Research Institute DNA-methylase linking reaction
GB9703369D0 (en) 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
US9005613B2 (en) * 2003-06-16 2015-04-14 Immunomedics, Inc. Anti-mucin antibodies for early detection and treatment of pancreatic cancer
WO2007013360A2 (en) * 2005-07-27 2007-02-01 Oncotherapy Science, Inc. Pancreatic cancer related gene cst6 and gabrp
AU2008231575A1 (en) * 2007-03-27 2008-10-02 Immunovia Ab Protein signature/markers for the detection of adenocarcinoma
MX350533B (es) * 2010-08-13 2017-09-08 Somalogic Inc Biomarcadores de cancer pancreatico y usos de los mismos.
GB201103726D0 (en) * 2011-03-04 2011-04-20 Immunovia Ab Method, array and use thereof
US20150018235A1 (en) * 2012-01-13 2015-01-15 Oncocyte Corporation Methods and Compositions for the Treatment and Diagnosis of Pancreatic Cancer
KR20140094180A (ko) * 2013-01-21 2014-07-30 연세대학교 산학협력단 보체인자 b 단백질에 특이적으로 결합하는 폴리펩타이드 또는 항체를 포함하는 췌장암 진단용 조성물
US20160055297A1 (en) * 2013-04-17 2016-02-25 Lg Electronics Inc. Method for extracting biomarker for diagnosing pancreatic cancer, computing device therefor, biomarker for diagnosing pancreatic cancer and device for diagnosing pancreatic cancer including the same
BR112016007037B1 (pt) * 2013-10-01 2023-12-26 National Cancer Center Método para detectar câncer pancreático
KR20150129932A (ko) * 2014-05-12 2015-11-23 연세대학교 산학협력단 보체인자 b 단백질에 특이적으로 결합하는 항체를 포함하는 췌장암 진단용 키트
CN105092845A (zh) * 2015-07-10 2015-11-25 深圳市贝沃德克生物技术研究院有限公司 胰腺癌蛋白生物标记物、用途及其检测芯片和检测装置
GB201516801D0 (en) * 2015-09-22 2015-11-04 Immunovia Ab Method, array and use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004147656A (ja) * 2002-10-31 2004-05-27 F Hoffmann La Roche Ag 膵癌の診断および治療のための方法、ならびにそれらに有用な組成物
WO2013052480A1 (en) * 2011-10-03 2013-04-11 The Board Of Regents Of The University Of Texas System Marker-based prognostic risk score in colon cancer
WO2014160499A2 (en) * 2013-03-13 2014-10-02 Creatics Llc Methods and compositions for detecting pancreatic cancer
WO2015067969A2 (en) * 2013-11-11 2015-05-14 Immunovia Ab Method, array and use thereof
WO2015171736A2 (en) * 2014-05-07 2015-11-12 University Of Utah Research Foundation Biomarkers and methods for diagnosis of early stage pancreatic ductal adenocarcinoma

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANNA SANDSTROM: "Plasma protein profiling in a stage defined pancreatic cancer cohort e Implications for early diagno", MOLECULAR ONCOLOGY, vol. 10, JPN6021010738, 12 July 2016 (2016-07-12), pages 1305 - 1316, ISSN: 0004472859 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025534317A (ja) * 2022-09-28 2025-10-15 ヒューベット バイオ，インコーポレーテッド 膵臓癌診断用組成物

Also Published As

Publication number Publication date
US20220206004A1 (en) 2022-06-30
RU2018138639A3 (cg-RX-API-DMAC10.html) 2020-10-30
JP2021165745A (ja) 2021-10-14
GB201608192D0 (en) 2016-06-22
EP3907509A2 (en) 2021-11-10
EP3907509A3 (en) 2021-12-29
KR20190005858A (ko) 2019-01-16
US20200011872A1 (en) 2020-01-09
WO2017194613A2 (en) 2017-11-16
RU2018138639A (ru) 2020-06-10
BR112018073178A2 (pt) 2019-02-19
EP3455632A2 (en) 2019-03-20
CN109564221A (zh) 2019-04-02
WO2017194613A3 (en) 2017-12-21
CA3022022A1 (en) 2017-11-16
MX2018013621A (es) 2019-04-25
AU2017261762A1 (en) 2018-11-15
IL262824A (en) 2018-12-31

Similar Documents

Publication Publication Date Title
JP2021165745A (ja) 方法、アレイ、およびその使用
KR102014890B1 (ko) 췌장암의 존재를 결정하기 위한 방법, 어레이 및 그의 용도
KR102240473B1 (ko) 방법, 어레이 및 그의 용도
EP3353552B1 (en) Method and array for diagnosing pancreatic cancer in an individual
US20190382849A1 (en) Methods, arrays and uses thereof
US11320436B2 (en) Methods, arrays and uses thereof
JP5422785B2 (ja) 質量分析法を利用した複数癌腫の血液検出のための方法および生物マーカー
CN103038642B (zh) 方法、阵列及其用途
US20170192004A1 (en) Methods and Arrays for Use in the Same
KR102208140B1 (ko) 전립선암의 바이오마커 검출에서 사용하기 위한 방법 및 어레이
JP2007263896A (ja) 肺癌患者の術後予後予測のための生物マーカー及びその方法
US20140248297A1 (en) Predictors of response to immunotherapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200508

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200508

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210329

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210326

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211108